Abstract
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease,whose exact pathogenesis is not fully clear as yet.The abnormal activation of B cells plays an important role in the development of SLE,and B cell-activating factor (BAFF) is critical for the abnormal activation of B cells.Belimumab is a human monoclonal antibody which can selectively recognize and block soluble BAFF.The efficacy and safety of belimumab have been confirmed for the treatment of SLE in randomized,double-blind,large-scale clinical trials.As a biological agent with high efficacy,few side effects and high tolerability,belimumab is a promising drug for SLE. Key words: Lupus erythematosus, systemic; Belimumab; Molecular targeted therapy
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
